Just as monitoring individual system variability offers an evaluation of the underlying individual system producing those dynamics, evaluating multisystem variability provides an evaluation of the whole, namely the systemic host response.
Systemic glucose variability has been shown to be associated with poor outcome in critically ill patients.
Increased systemic glucose variability is associated with cerebral metabolic distress and increased hospital mortality.
In this study we demonstrated an association between increased systemic glucose variability with cerebral metabolic distress and mortality after SAH.
In this study, we sought to understand better the potential role of increased systemic glucose variability in cerebral oxidative metabolism and potentially secondary brain injury.
Serum glucose levels can affect cerebral glucose metabolism, so systemic glucose variability may be associated with poor outcome in critically ill patients [ 25].
Systemic glucose variability has been associated with mortality in mixed populations of critically ill patients [ 29- 31] and after traumatic brain injury [ 26, 49].
Increased systemic glucose variability was independently associated with cerebral metabolic distress, as measured by microdialysis, in patients after poor-grade SAH.
The database described above also contains observations of systemic pharmacodynamic variability for 13 chemicals (Table VI in Hattis et al. [ 79]).
